Truist raises target for SI-BONE stock from USD 23.00 to USD 25.00

Published on 10/20/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SI-BONE raised 2026 sales guidance to USD 231.00-233.00 million on August 3, 2026. SI-BONE stock costs EUR 18.25 on October 20, 2026.

Target and operating figures

Truist Securities raised its SI-BONE target to USD 25.00 from USD 23.00 on October 14, 2026.
Second-quarter 2026 revenue reached USD 56.01 million versus USD 55.34 million consensus.
SI-BONE stock costs EUR 18.25 at Lang & Schwarz on October 20, 2026 at 10:07 p.m. CEST.
SI-BONE is scheduled to report third-quarter 2026 results on November 2, 2026.

SIBN, US8257041090, Illustration mit AI erstellt.

SI-BONE, Inc. (ISIN US8257041090) drew a higher Truist Securities target on October 14, 2026, when the firm lifted its price objective from USD 23.00 to USD 25.00 while maintaining a Buy rating, Markets Insider reported. Against the Nasdaq price of USD 20.54 on October 20, 2026, the target stands 21.71 percent above the stock. At Lang & Schwarz, SI-BONE was trading at EUR 18.25 on October 20, 2026 at 10:07 p.m. CEST.

Revenue and guidance moved higher

SI-BONE reported USD 56.01 million of revenue for the second quarter of 2026, compared with USD 55.34 million consensus, while its adjusted loss was USD 0.09 per share against an expected USD 0.15 loss. The figures and the raised full-year sales outlook came from the August 3, 2026 results update carried by Sept Investing. SI-BONE lifted its 2026 sales guidance to USD 231.00 million to USD 233.00 million from USD 230.00 million to USD 233.00 million.

Stock stays below its yearly high

The Nasdaq quote stood at USD 20.54 after hours on October 20, 2026 at 4:00 p.m. ET. SI-BONE's 52-week range was USD 11.48 to USD 21.89, placing the stock 6.17 percent below its yearly high and 78.92 percent above its yearly low. Trading volume reached 590,820 shares, while market capitalization stood at USD 920.6 million.

What does the target imply?

The USD 25.00 Truist target is 21.71 percent above the Nasdaq price of USD 20.54. The comparison is useful because SI-BONE remains loss-making on the reported figures, even as revenue expanded and the company raised its full-year sales range. SI-BONE develops minimally invasive implants for sacropelvic disorders, including its iFuse platform, according to the company's investor-relations page at SI-BONE.

November reporting date approaches

SI-BONE is scheduled to release its third-quarter 2026 financial results on November 2, 2026, according to the corporate calendar information carried by Markets Insider. That report will provide the next periodized test of the USD 231.00 million to USD 233.00 million full-year sales outlook.